- Home
- ALT vs NMAI Comparison
ALT vs NMAI Comparison
Compare ALT & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALT | NMAI |
|---|---|---|
| Founded | 1997 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 435.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ALT | NMAI |
|---|---|---|
| Price | $4.54 | $13.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 6.0M | 74.8K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | ★ $20,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.03 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $10.60 |
| 52 Week High | $7.73 | $12.55 |
Technical Indicators
Market Signals| Indicator | ALT | NMAI |
|---|---|---|
| Relative Strength Index (RSI) | 58.55 | 54.05 |
| Support Level | $4.03 | $13.06 |
| Resistance Level | $4.40 | $13.38 |
| Average True Range (ATR) | 0.26 | 0.13 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 99.56 | 60.18 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.